Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 highlights on managing difficult to treat cancers

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.09.17
Views: 2986

Prof Richard Finn, Prof Viktor Grünwald, Prof Arndt Vogel, Prof René Adam

Prof Viktor Grünwald (Hannover Medical School, Hannover, Germany), Prof Richard Finn (Geffen School of Medicine at UCLA Medical Center, Los Angeles, USA), Prof Arndt Vogel (Hannover Medical School, Hannover, Germany), and Prof René Adam (Hôpital Paul-Brousse, Villejuif, France) discuss the key ESMO 2017 clinical highlights on managing patients with hepatocellular carcinoma, biliary tract carcinoma and renal cell carcinoma.

These 3 fields have a high unmet need and require new surgical and therapeutic approaches.

The balance of clinical endpoints in PFS and OS need to be taken into consideration when managing the QOL benefits for patients.

The magnitude of responses with new and existing agents means that clinicians will be able to improve upon the current standard of care and collaborate as an MDT to change the outlook in these difficult to treat cancers.

The panel discuss advances with the latest generation of tyrosine kinase inhibitors (TKIs) and the introduction of immunotherapy in novel combinations with targeted agents, and the ongoing utility of chemo-radiation and surgical approaches. 

For more on regorafenib to treat hepatocellular carcinoma, read more about the FDA approval in this indication here.

For more on lenvatinib as an agent in combinations to treat renal cell carcinoma, ecancer spoke with Dr Chung-Han Lee, here.

This programme has been supported by an unrestricted educational grant from Eisai.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation